Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (201-210 of 301) with videos related to

Pageof 31
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 2, 2024
The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan DrugsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.
JAMA|September 29, 2025
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene TherapiesJames D Chambers, Julia A Rucker, Daniel E Enright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Impact of referral patterns on the use of chemotherapy for lung cancerCraig C Earle, Peter J Neumann, Richard D Gelber, et al.
Journal of General Internal Medicine|April 16, 2020
Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan DrugsJames D Chambers, Madison C Silver, Flora C Berklein, et al.
Journal of Managed Care Pharmacy : JMCP|May 4, 2010
Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitusJoseph Menzin, Jonathan R Korn, Joseph Cohen, et al.
Health Economics|May 6, 2004
When does quality-adjusting life-years matter in cost-effectiveness analysis?Richard H Chapman, Marc Berger, Milton C Weinstein, et al.
Medical Care|August 29, 2022
Effect of the 2012 US Preventive Services Task Force Recommendations on Prostate-Specific Antigen Screening in a Medicare Advantage PopulationYingying Zhu, Benjamin Koethe, Daniel A Ollendorf, et al.
Pharmacoeconomics|September 24, 2021
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 PandemicYumi Asukai, Andrew Briggs, Louis P Garrison, et al.
The International Journal of Cardiovascular Imaging|May 7, 2010
Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?Hansel J Otero, Frank J Rybicki, Dan Greenberg, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 29, 2025
Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation StudyYingying Zhu, Natalia Olchanski, Karen M Freund, et al.
Pageof 31

Showing results (201-210 of 301) with videos related to

Sort By:
Pageof 31
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 2, 2024
The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan DrugsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.
JAMA|September 29, 2025
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene TherapiesJames D Chambers, Julia A Rucker, Daniel E Enright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Impact of referral patterns on the use of chemotherapy for lung cancerCraig C Earle, Peter J Neumann, Richard D Gelber, et al.
Journal of General Internal Medicine|April 16, 2020
Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan DrugsJames D Chambers, Madison C Silver, Flora C Berklein, et al.
Journal of Managed Care Pharmacy : JMCP|May 4, 2010
Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitusJoseph Menzin, Jonathan R Korn, Joseph Cohen, et al.
Health Economics|May 6, 2004
When does quality-adjusting life-years matter in cost-effectiveness analysis?Richard H Chapman, Marc Berger, Milton C Weinstein, et al.
Medical Care|August 29, 2022
Effect of the 2012 US Preventive Services Task Force Recommendations on Prostate-Specific Antigen Screening in a Medicare Advantage PopulationYingying Zhu, Benjamin Koethe, Daniel A Ollendorf, et al.
Pharmacoeconomics|September 24, 2021
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 PandemicYumi Asukai, Andrew Briggs, Louis P Garrison, et al.
The International Journal of Cardiovascular Imaging|May 7, 2010
Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?Hansel J Otero, Frank J Rybicki, Dan Greenberg, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 29, 2025
Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation StudyYingying Zhu, Natalia Olchanski, Karen M Freund, et al.
Pageof 31